Ready-to-use materials and in-line dilution can streamline overall bioprocessing operations.

Improving mAb Manufacturing Productivity

Bioreactor technology advances can offer seamless manufacturing scale-up.

Cell Culture Scale-up Challenges

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

Articles

PAT advances are enabling improved process understanding, process control, and error prevention.

Control Strategies for Perfusion Cell Culture

An innovation such as synthetic biology can develop a consistently stable starting cell line for cell therapy source material.

Synthetic Biology Offers a Solution to Cell Therapy Source Material Constraints

Melisa Carpio is a global technology consultant for Cell Culture Technologies at Sartorius North America.

Bioreactor technology advances can offer seamless manufacturing scale-up and can reduce the timeline and cost of biologics production.

Current Challenges with Cell Culture Scale-up for Biologics Production 

This article will explore the traditional path from the laboratory to the clinic and how the fixed-bed technology provides an alternative solution to meet commercial demands.

Commercial Production of Gene Therapies Using Suspension or Adherent Cell Lines 

Process modeling offers an opportunity to troubleshoot for and anticipate difficult aspects of a bioprocess.

Using Process Modeling to Troubleshoot a Bioprocess

Innovative approaches, including ready-to-use materials and in-line dilution, can significantly streamline overall bioprocessing operations.

Improving mAb Manufacturing Productivity by Optimizing Buffer and Media Prep Process Flow

Therapies for early and late treatment and passive immunization of COVID-19 are needed and can be developed using antibodies from recovered patients.

Plasma-Based Antibody Therapies Battle Against COVID-19

Synthetic biology has advanced the scope and scale with which biologically derived therapeutics can be developed.

Biopharmaceutical Manufacturing and the Power of Synthetic Biology

New bioreactor designs, coupled with better media, process intensification and analytics, continue to improve upstream bioprocessing.

Bioreactors Redefine Upstream Productivity

The new BIOSTAT STR Generation 3 with BIOBRAIN bioproduction platform offers process intensification with automated feed and bleed and integrated cell retention functionality.

Upstream Processing

Improving mAb Manufacturing Productivity

Cell Culture Scale-up Challenges